Interferon for interferon naive patients with chronic hepatitis C

Area of Science:

• Hepatology and Viral Gastroenterology
• Clinical Trial Meta-Analysis
• Pharmacological Efficacy Studies

Background:

• Previous meta-analyses confirmed interferon's efficacy for chronic hepatitis C (HCV) in naive patients.
• Additional clinical trials have since been published, necessitating an updated evaluation.
• This review focuses on interferon's role in treatment-naive chronic HCV patients.

Purpose of the Study:

• To evaluate interferon treatment response in naive chronic hepatitis C patients.
• To investigate the impact of interferon dose and duration on treatment outcomes.
• To assess treatment response in patients with cirrhosis and normal aminotransferases.

Main Methods:

• Systematic search of Cochrane Controlled Trials Register, MEDLINE, and reference lists.
• Inclusion of randomized clinical trials comparing interferon to placebo or different interferon regimens.
• Primary outcome: sustained disappearance of serum HCV RNA (virologic sustained response).

Main Results:

• Interferon (3 MU thrice weekly for 12 months) significantly increased virologic sustained response (17% vs. 3% in controls).
• Higher doses (6 MU) and longer durations (≥12 months) demonstrated increased efficacy but more adverse events.
• Interferon showed similar benefits in cirrhotic patients, but efficacy was unproven in those with normal aminotransferases.

Conclusions:

• Interferon is effective for viral clearance and improving liver health in naive chronic HCV patients.
• Optimizing dose and duration enhances efficacy, though it correlates with increased adverse events.
• Interferon benefits are comparable in cirrhotic patients; efficacy in normal aminotransferase patients requires further study.